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Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric
basic helix-loop-helix transcription factor composed of
HIF-1␣ and HIF-1␤/aryl hydrocarbon nuclear translocator subunits. HIF-1 expression is induced by hypoxia,
growth factors, and activation of oncogenes. In response
to hypoxia, HIF-1 activates the expression of many
genes including vascular endothelial growth factor
(VEGF) and erythropoietin. HIF-1 and VEGF play an
important role in angiogenesis and tumor progression.
Vanadate is widely used in industry, and is a potent
inducer of tumors in humans and animals. In this study,
we demonstrate that vanadate induces HIF-1 activity
through the expression of HIF-1␣ but not HIF-1␤ subunit, and increases VEGF expression in DU145 human
prostate carcinoma cells. We also studied the signaling
pathway involved in vanadate-induced HIF-1␣ and
VEGF expression and found that phosphatidylinositol
3-kinase/Akt signaling was required for HIF-1 and VEGF
expression induced by vanadate, whereas mitogen-activated protein kinase pathway was not required. We also
found that reactive oxygen species (ROS) were involved
in vanadate-induced expression of HIF-1 and VEGF in
DU145 cells. The major species of ROS responsible for
the induction of HIF-1 and VEGF expression was H2O2.
These results suggest that the expression of HIF-1 and
VEGF induced by vanadate through PI3K/Akt may be an
important signaling pathway in the vanadate-induced
carcinogenesis, and ROS may play an important role.

Hypoxia-inducible factor 1 (HIF-1)1 is a heterodimer of
HIF-1␣ and HIF-1␤ subunits, which contain basic helix-loophelix PAS domains (1, 2). HIF-1␣ is a unique subunit tightly
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regulated in response to hypoxia (2, 3), whereas HIF-1␤ is
identical to the aryl hydrocarbon nuclear translocator that
forms heterodimers with the aryl hydrocarbon receptor in cells
(2, 4). HIF-1 regulates the expression of many genes including
vascular endothelial growth factor (VEGF), erythropoietin,
heme oxygenase 1, aldolase, enolase, and lactate dehydrogenase A (5– 8). The levels of HIF-1 activity in cells correlate with
tumorigenicity and angiogenesis in nude mice (9, 10). HIF-1 is
also induced by the expression of oncogenes such as v-Src and
Ras (9, 11), and is overexpressed in many human cancers (12).
Recent studies indicate that both phosphatidylinositol 3-kinase
(PI3K)/Akt and MAP kinase pathway are involved in HIF-1
expression induced by growth factors (13–16). HIF-1␣ interacts
with tumor suppressor Von Hippel-Lindau protein. The mutation of Von Hippel-Lindau protein in human cancers results in
the constitutive expression of HIF-1 under nonhypoxic conditions (17). HIF-1␣ is degraded by the proteasome pathway
(18 –21). The regulation of HIF-1 by Von Hippel-Lindau protein
and cellular oxygen was recently shown to be mediated through
the prolyl hydroxylation of HIF-1␣ at Pro564 by three mammalian PHDs proteins (22–24). One of the major genes regulated
by HIF-1 is VEGF (5, 25). VEGF plays a key role in tumor
progression and angiogenesis. There is a strong correlation
between VEGF expression and blood vessel density in many
tumor types (26). Inhibition of VEGF expression and of its
receptor function dramatically decreases the tumor growth,
invasion, and metastasis in animal models (27–30). Somatic
mutations such as oncogene Ras activation and tumor suppressor gene p53 inactivation also increase VEGF expression (26).
Vanadium is a widely distributed trace metal. The burning of
fossil fuels (petroleum, coal, and oil) in power and heat producing plants causes widespread discharge of vanadium into the
environment (31, 32). Vanadium exists in oxidation states
ranging from ⫺1 to ⫹5. Among these oxidation states, the
pentavalent state is the most stable form. Previous studies
provide evidence that in mammalian systems vanadium(V) is
more toxic than vanadium(IV). The data on the carcinogenic
activity of vanadium is limited. Epidemiological studies have
shown a correlation between vanadium exposure and the incidence of cancer in humans (33–36). Some reports indicate that
vanadium increases the frequency of micronuclei and polyploid
cells, decreases mitotic index, and induces DNA single strand
breaks and DNA-protein cross-links (37–39). Previous in vitro
studies using cultured mouse embryo fibroblast BALB/3T3
cells and the Syrian hamster embryo cells demonstrated that
this metal is a carcinogen (40 – 43). Although the mechanisms
of vanadate-induced carcinogenesis are not fully understood,
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FIG. 1. Induction of HIF-1 expression by vanadate. A, DU145
cells were treated without (lane 1) or with 25–200 M vanadate (lanes
2–5) for 6 h. B, DU145 cells were treated without (lane 1) and with 100
M vanadate for 1, 3, 6, 12, and 24 h, respectively. Cellular extracts
were prepared and subjected to immunoblot assay using an anti-HIF-1␣
monoclonal antibody. The blot was then stripped and detected for
HIF-1␤ expression using antibodies against HIF-1␤. The immunoblot
signals were quantified using molecular analyst/PC densitometry software (Bio-Rad). The mean densitometry data from independent experiments (one of which is shown here) were normalized to the result
obtained in cells in the absence of vanadate (control). Plots are mean ⫾
S.E. values (n ⫽ 3); *, p ⬍ 0.05 compared with the control; **, p ⬍ 0.01
compared with the control.

reactive oxygen species (ROS) are considered to play an important role (44, 45). It has been reported that upon reduction by
cellular reactants, vanadate is able to generate a whole spectrum of ROS, i.e. O2. , H2O2, and 䡠OH. It is well known that ROS
play an important role in carcinogenesis induced by a variety of
carcinogens. Through ROS-mediated reaction, vanadate is able
to induce activation of activator protein-1 expression (44, 45).
Recent studies have found that vanadium is able to mimic the
effect of insulin (46 – 49). Therefore, we tested whether vanadate is able to induce the expression of HIF-1␣ and VEGF in
DU145 human prostate carcinoma cells and evaluated the role
of individual ROS. The following specific questions were addressed: (a) whether vanadate is able to induce HIF-1 and
VEGF expression; (b) which signaling pathway(s) is/are involved in vanadate-induced expression of HIF-1␣ protein; (c)
whether ROS species are involved in vanadate-induced HIF-1␣
and VEGF expression; and (d) which species of ROS play a
critical role.
MATERIALS AND METHODS

Reagents and Cell Culture—Sodium orthovanadate, NADPH, superoxide dismutase, sodium formate, deferoxamine, diphenylene iodonium
(DPI), and rotenone were purchased from Sigma. Catalase was purchased from Roche Molecular Biochemicals (Indianapolis, IN). Antibodies against HIF-1␣ and HIF-1␤ were from Transduction Laboratories
(Lexington, KY), phospho-Akt (Ser473) and Akt antibodies were from
Cellular Signaling (Beverly, MA). The human VEGF immunoassay kit
was from R&D Systems (Minneapolis, MN).
The human prostate cancer cell line DU145 was maintained in minimum essential medium (MEM) (Invitrogen) supplemented with 10%
fetal bovine serum (FBS), 3% chicken serum, 2 mM L-glutamine, 100
units/ml penicillin, and 100 g/ml streptomycin, and cultured at 37 °C
in a 5% CO2 incubator. The cells form a monolayer at confluence.
Trypsin (0.25%)/EDTA solution was used to detach the cells from the
culture flask for passing the cells.
Immunoblot Analysis—The cells were plated in a 60-mm culture dish
and treated with vanadate. Cells were lysed in RIPA buffer (150 mM
NaCl, 100 mM Tris (pH 8.0), 1% Triton X-100, 1% deoxycholic acid, 0.1%
SDS, 5 mM EDTA, and 10 mM NaF) supplemented with 1 mM sodium
vanadate, 2 mM leupeptin, 2 mM aprotinin, 1 mM phenylmethylsulfonyl
fluoride, 1 mM dithiothreitol, and 2 mM pepstatin A on ice for 30 min.
After centrifugation at 14,000 rpm for 15 min, the supernatant was
harvested as the total cellular protein extracts and stored at ⫺70 °C.
The protein concentration was determined using Bio-Rad protein assay

FIG. 2. Effect of pharmacological inhibitors of PI3K and MEK
on HIF-1 expression induced by vanadate. DU145 cells were cultured in MEM supplemented with 10% FBS for 24 h at 37 °C in 5% CO2
incubator, followed by the addition of LY294002 (A), wortmannin (B),
and PD98059 (C) at the concentrations indicated, and incubated for 30
min. Cells were then treated with 100 M vanadate for an additional
6 h. Cellular lysates were prepared and used for immunoblot assay
using antibodies against HIF-1␣ and HIF-1␤ as indicated. The immunoblot signals were quantitated and analyzed as described in the legend
to Fig. 1. Plots are mean ⫾ S.E. (n ⫽ 3); **, p ⬍ 0.01 compared with the
control; ##, p ⬍ 0.01 compared with the values from the cells treated by
vanadate in the absence of LY294002 and wortmannin.
reagents. The total cellular protein extracts were separated by SDSPAGE, and transferred to nitrocellulose membrane in 20 mM Tris-HCl
(pH 8.0) containing 150 mM glycine and 20% (v/v) methanol. Membranes were blocked with 5% nonfat dry milk in 1⫻ TBS containing
0.05% Tween 20 and incubated with antibodies against HIF-1␣, HIF1␤, phospho-Akt (Ser473), and Akt. Protein bands were detected by
incubation with horseradish peroxidase-conjugated antibodies
(PerkinElmer Life Sciences), and visualized with enhanced chemiluminescence reagent (PerkinElmer Life Sciences).
PI3K Assay—Cells were washed with ice-cold PBS and scraped from
the plates, and centrifuged at 4,000 rpm for 5 min. The cell pellet was
incubated for 20 min on ice in lysis buffer (150 mM NaCl, 100 mM
Tris-HCl (pH 8.0), 1% Triton X-100, 5 mM EDTA, 10 mM NaF) supplemented with 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride,
1 mM sodium vanadate, 2 mM leupeptin, and 2 mM aprotinin, and
centrifuged at 15,000 ⫻ g for 15 min to clarify the supernatants. PI3K
activity was analyzed using 400 g of protein extracts and anti-p110
antibodies as described (28, 29). Briefly, 400 g of total protein was
incubated with 20 l of protein A/G plus agarose for 1 h at 4 °C on a
rotator, followed by spinning at 3,000 rpm for 3 min. The supernatant
was then incubated with 10 l of antibodies against p110 subunit of
PI3K for 1 h at 4 °C. Protein A/G-agarose beads (30 l) were added for
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FIG. 3. Effect of vanadate on PI3K
activity and phosphorylation of Akt.
A, DU145 cells were treated with various
concentrations of vanadate for 2 h. B, the
cells were treated with 100 M vanadate
for different time periods as indicated.
The total protein extracts were prepared
and used for determining PI3K activity (A
and B). C, the cells were treated with
certain concentrations of vanadate for 2 h.
D, the cells were exposed to 100 M vanadate from 0 to 4 h as indicated. The total
cellular protein extracts were prepared
and subjected to immunoblot assay with
antibodies against phospho-Akt (Ser473)
and Akt (C and D). The immunoblot signals were quantitated and analyzed as
described in the legend to Fig. 1. Plots are
mean ⫾ S.E. (n ⫽ 3); *, p ⬍ 0.05 compared
with the control; **, p ⬍ 0.01 compared
with the control.

an additional 1 h. The beads were then pelleted and washed sequentially with TNE buffer (containing 20 mM Tris, pH 7.5, 100 mM NaCl,
and 1 mM EDTA), five times; and once with 20 mM HEPES. PI3K assays
were performed using phosphatidylinositol as substrate in a final volume of 50 l containing 20 mM HEPES (pH 7.5), 10 mM MgCl, 2 Ci of
[␥-32P]ATP, 60 M ATP, and 0.2 mg/ml sonicated phosphatidylinositol.
Reactions were carried out for 15 min at room temperature and extracted by the addition of 80 l of 1 M HCl and 160 l of chloroform/
methanol (1:1). After centrifugation, the organic phase was evaporated
to dryness and separated on a TLC plate. PI3K activity was analyzed by
the incorporation of 32P into phosphorylated lipids, and detected by
autoradiography.
Densitometry Analysis—Autoradiographic signals of immunoblot
and PI3K activity assays were quantified using molecular analyst/PC
densitometry software (Bio-Rad). Mean densitometry data from independent experiments were normalized to result in cells in the control.
The data were presented as the mean ⫾ S.E., and analyzed by the
Student’s t test.
VEGF Assay—DU145 cells were plated in a 6-well plate at a density
of 1 ⫻ 105 cells/well in MEM and incubated overnight before the cells
were subjected to treatment. After treatment, the cell culture media
were removed for storage at ⫺80 °C. Levels of VEGF protein in the
medium were determined by ELISA using a commercial kit (R&D
Systems, Minneapolis, MN). Briefly, 200 l of standards or cell culture
supernatant were added to the wells of a microplate that was pre-coated
with a monoclonal antibody specific for VEGF and incubated for 2 h at
room temperature. After washing away any unbounded substances, an
enzyme-linked polyclonal antibody against VEGF conjugated to horseradish peroxidase was added to the wells and incubated for 2 h at room
temperature. Following a wash, 200 l of substrate solution was added

to the wells and incubated for 30 min, and then 50 l of stop solution
was added to stop color development. The optical density of each well
was determined using a microplate reader at 450 nm. The experiments
were repeated twice with two replications per experiment. Mean values
from these samples were analyzed.
ESR Measurements—The ESR spin trapping technique with DMPO
as the spin trap was used to detect free radical generation. This technique involves the addition-type reaction of a short-lived radical with a
diamagnetic compound (spin trap) to form a relative long-lived free
radical product (spin adduct), which can be studied by conventional
ESR (50). The intensity of the spin adduct signal corresponds to the
amount of short-lived radicals trapped, and the hyperfine couplings of
the spin adduct were generally characteristic of the original trapped
radicals. All ESR measurements were conducted using a Varian E9
ESR spectrometer and a flat cell assembly as described (51, 52). Hyperfine couplings were measured (to 0.1 G) directly from magnetic field
separation using potassium tetraperoxochromate (K3CrO8) and 1,1diphenyl-2-picrylhydrazyl as reference standards. Reactants were
mixed in test tubes in a total final volume of 500 l and transferred to
a flat cell for ESR measurement.
Measurements of Cellular Hydrogen Peroxide (H2O2)—Cellular H2O2
was determined using a quantitative H2O2 assay kit (BIOXYTECH,
Portland, OR). The assay was performed according to the protocol
provided by the manufacturer. This assay is based on the oxidation of
ferrous ions (Fe2⫹) to ferric ions (Fe3⫹) by H2O2 under acidic conditions.
The ferric ion binds with the indicator dye xylenol orange to form a
stable colored complex that can be measured at 560 nm. Briefly, cells
were pretreated with vanadate and with or without antioxidants. The
aliquots of media were incubated at 25 °C for 30 min with 100 l of a
10⫻ xylenol orange stock solution (xylenol orange (10 M),
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FIG. 4. Effect of PI3K inhibitors on
PI3K activity and Akt phosphorylation. DU145 cells were cultured in MEM
supplemented with 10% FBS for 24 h at
37 °C in a 5% CO2 incubator, followed by
pretreatment with LY294002 or wortmannin for 30 min as indicated. The cells
were then treated with 100 M vanadate
for an additional 2 h. A, the total cellular
protein extracts were prepared and used
for determining PI3K activity (A). The
cells were incubated with LY294002 (B)
or wortmannin (C) for 30 min, followed by
treatment with 100 M vanadate for 2 h.
The total cellular protein extracts were
prepared and subjected to immunoblot assay with antibodies against phospho-Akt
(Ser473) and Akt (D and C). The immunoblot signals were quantified and analyzed. Plots are mean ⫾ S.E. values (n ⫽
3); **, p ⬍ 0.01 compared with the control;
##, p ⬍ 0.01 compared with the values
from the cells treated by vanadate in the
absence of inhibitors.

FIG. 5. Effect of rapamycin on HIF-1 expression induced by
vanadate. DU145 cells were cultured in MEM supplemented with 10%
FBS for 24 h at 37 °C in a 5% CO2 incubator. The cells were incubated
with a mTOR/FRAP inhibitor, rapamycin, at the concentrations indicated for 30 min, followed by treatment with 100 M vanadate for 6 h.
Cellular lysates were prepared and used for immunoblot assay using
antibodies against HIF-1␣ and HIF-1␤. The immunoblot signals were
quantitated and analyzed. Mean ⫾ S.E. (n ⫽ 3) are shown. **, p ⬍ 0.01
compared with the control; ##, p ⬍ 0.01 compared with the values from
the cells treated by vanadate in the absence of rapamycin.
Fe(NH4)2(SO4)䡠6H2O (2.5 M), H2SO4 (25 mM)) after which the absorbance was read at 560 nm. The concentration of H2O2 was determined
from a standard curve.
Superoxide Anion (O 2. ) Assay—Dihydroethidium (HE) is a specific
dye for O2. . HE was oxidized by O2. to ethidium that stains nucleus to

FIG. 6. VEGF protein secretion by DU145 cells treated with
vanadate. DU145 cells were seeded in a 6-well plate at a density of 1 ⫻
6
10 cells/well in MEM supplemented with 10% FBS and incubated for
24 h at 37 °C in a 5% CO2 incubator. The cells were treated without (●)
and with 50 M vanadate (E) for different time periods as indicated. The
concentrations of VEGF protein in the culture media were determined
by ELISA. The results represent the mean values of VEGF concentrations from duplicate samples of each experiment and three separate
experiments. The asterisk (*) indicates the levels of VEGF significantly
increased compared with the control (p ⬍ 0.01).
form a bright fluorescent red (53). The cells were plated onto a glass
coverslip in the 12-well plate at 1 ⫻ 105 cells/well 24 h before treatment.
HE was added into the cell culture 30 min before vanadate treatment
was completed. After being stained, the cells were washed in PBS and
fixed with 10% buffered formalin. The coverslip was mounted on a glass
slide and observed using a Saratro 2000 (Amersham Biosciences) laser
scanning confocal microscope (Optiphot-2, Nikon, Inc., Melville, PA)
fitted with an argon-ion laser.
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FIG. 7. Effect of inhibitors of PI3K and MEK on VEGF expression induced by vanadate. DU145 cells were seeded in a 6-well plate
at a density of 1 ⫻ 106 cells/well in MEM supplemented with 10% FBS
and incubated for 24 h at 37 °C in a 5% CO2 incubator, followed by
pretreatment with PI 3-kinase inhibitors, LY294002 (10 and 40 M) and
wortmannin (50 and 200 nM), or the MEK inhibitor, PD98059 (25 and
50 M). Cells were then treated with 50 M vanadate(V) for 24 h. VEGF
protein concentrations in the culture media were determined by ELISA.
The results represent the mean values of VEGF concentrations from
three separate experiments with duplicate samples of each experiment.
Oxygen Consumption Measurements—Oxygen consumption measurements were carried out with a Gilson oxygraph equipped with a Clark
electrode (Gilson Medical Electronic, Middleton, WI). These measurements were made from a mixture containing 1 ⫻ 106 cells/ml and various
treatments in a total volume of 1.5 ml. The oxygraph was calibrated with
media equilibrated with oxygen of known concentrations.
RESULTS

Vanadate Induces HIF-1 Expression—To determine whether
vanadate could induce HIF-1 expression, DU145 cells were
treated with various concentrations of vanadate for 6 h, and the
total cellular protein extracts were prepared for immunoblot
assays of HIF-1␣ and HIF-1␤ protein levels. As shown in Fig.
1A, levels of HIF-1␣ protein were induced by vanadate in a
dose-dependent manner, whereas the levels of HIF-1␤ protein
were not altered. The maximum expression of HIF-1␣ was
induced by 100 M vanadate (Fig. 1A). To determine the kinetics of HIF-1␣ expression induced by vanadate, cells were
treated with 100 M vanadate for various times as indicated,
and cellular protein extracts were prepared for analysis of
HIF-1␣ and HIF-1␤ protein levels. As shown in Fig. 1B, vanadate-induced HIF-1␣ expression in a time-dependent manner,
whereas it did not alter HIF-1␤ expression. The maximum
induction of HIF-1␣ expression was at 6 h after the treatment.
The prolonged exposure of cells to vanadate resulted in the
decrease of HIF-1␣ protein levels, possibly because of the apoptosis of the cells induced by this metal (data not shown).
PI3K but Not Mitogen-activated Protein Kinase/ERK Is Required in Vanadate-induced HIF-1␣ Expression—To determine
whether the PI3K signaling pathway was required for HIF-1␣
expression induced by vanadate, DU145 cells were pretreated
with PI3K inhibitors, LY294002 and wortmannin. The cells
were then exposed to vanadate for 6 h, and total cellular protein extracts were prepared for immunoblot assays of HIF-1␣
and HIF-1␤ protein levels. As shown in Fig. 2, A and B, PI3K
inhibitors, LY294002 and wortmannin, were able to inhibit
vanadate-induced HIF-1␣ expression in a dose-dependent manner, whereas these inhibitors did not change HIF-1␤ protein
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FIG. 8. Effects of antioxidants on vanadate(V)-induced ROS
generation. 1 ⫻ 106 cells were incubated in PBS containing 100 mM
DMPO and 1 mM vanadate(V) with or without antioxidants, DPI and
rotenone. ESR spectra were recorded for 30 min. A, DU145 cells only; B,
cells ⫹ vanadate; C, cells ⫹ vanadate ⫹ superoxide dismutase (1000
units/ml); D, cells ⫹ vanadate ⫹ catalase (5,000 units/ml); E, cells ⫹
vanadate ⫹ sodium formate (2 mM); F, cells ⫹ vanadate ⫹ NADPH (1
mM); G, cells ⫹ vanadate ⫹ DPI (20 M); H, cells ⫹ vanadate ⫹ rotenone
(50 M).
TABLE I
Relative free radical generation from cells stimulated by vanadate
The experimental conditions were the same as those described in the
legend to Fig. 8.
Reaction mixture

Cells
Cells
Cells
Cells
Cells
Cells
Cells
Cells
a

only
⫹ vanadate
⫹ vanadate
⫹ vanadate
⫹ vanadate
⫹ vanadate
⫹ vanadate
⫹ vanadate

⫹
⫹
⫹
⫹
⫹
⫹

superoxide dismutase
catalase
formate
NADPH
DPI
rotenone

Relative free radical
generationa

0.4 ⫾ 0.28
1.5 ⫾ 0.21
3.2 ⫾ 0.42
0.5 ⫾ 0.35
0.7 ⫾ 0.28
3.3 ⫾ 0.56
0.8 ⫾ 0.28
1.0 ⫾ 0.35

Data are presented as mean ⫾ S.E. (n ⫽ 3).

levels. These results suggest that PI3K activity was required
for the HIF-1␣ expression induced by vanadate. We also investigated whether mitogen-activated protein kinase activity was
required for HIF-1␣ expression induced by vanadate. Cells
were pretreated with various concentrations of PD98059, an
inhibitor of MAP kinase kinase (MEK). Cells were then treated
with 100 M vanadate for 6 h. As shown in Fig. 2C, addition of
PD98059 did not inhibit HIF-1␣ expression induced by vanadate. These results suggest that MEK activity was not required
for HIF-1␣ expression induced by vanadate.
Induction of PI3K Activity and Akt Phosphorylation by Vanadate—To further confirm that the PI3K activity was involved
in HIF-1␣ expression induced by vanadate, DU145 cells were
cultured in MEM supplemented with 10% FBS for 24 h at 37 °C
in a 5% CO2 incubator, followed by treatment with various
concentrations of vanadate for 2 h or 100 M vanadate for
various periods as indicated (Fig. 3). The cells were then
washed with cold 1⫻ PBS and the total cellular protein extracts (400 g) were used for determining PI3K activity. As
shown in Fig. 3A, PI3K activity was induced by vanadate in a
dose-dependent manner. The maximum induction of PI3K activity appeared at 100 M vanadate. To determine the kinetics
of PI3K activity induced by vanadate, the cells were treated
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FIG. 9. Analysis of ROS generation. A, determination of H2O2 by the quantitative H2O2 assay kit. 0.1 ml of cell suspension (1 ⫻ 106 cells/ml)
was incubated with or without vanadate and catalase as indicated, and then mixed with 1.0 ml of working reagent containing 2.5 mM ammonium
iron sulfate, 100 mM sorbitol, and 125 M xylenol orange for 30 min. The absorbance was measured at 560 nm. Values are mean ⫾ S.E. (n ⫽ 3).
* indicates a significant increase from control, whereas # indicates a significant decrease compared with the vanadate-treated group (p ⬍ 0.01).
B, determination of O2. by HE staining using confocal fluorescence microscopy. The cells were plated onto a glass coverslip in the 12-well plate at
1 ⫻ 105 cells/well 24 h before treatment. HE was added into the cell culture 30 min before treatment was completed. After being stained, the cells
were washed twice with PBS and fixed with 10% buffered formalin. The images were captured with a confocal fluorescence microscope. C, oxygen
consumption measurement. DU145 cells were incubated without or with 1 mM vanadate(V) and NADPH. Oxygen consumption was measured with
a Gilson oxygraph equipped with a Clark microelectrode as described under “Materials and Methods.” Values are mean ⫾ S.E. (n ⫽ 3). The double
asterisk (**) indicates a significant increase compared with the control without vanadate treatment (p ⬍ 0.01). ## indicates a significant increase
from the vanadate-treated sample (p ⬍ 0.01).

with 100 M vanadate for various times. PI3K activity was
induced 5 min, 15 min, 30 min, 1 h, and 2 h after the addition
of vanadate (Fig. 3B).
We also investigated endogenous Akt phosphorylation in
response to vanadate treatment. Cells were incubated with
certain concentrations of vanadate for 2 h, and the total cellular protein extracts were used to determine levels of phosphoAkt for Ser473 and Akt proteins using immunoblot assay. As
shown in Fig. 3C, vanadate induced Akt phosphorylation in a
dose-dependent manner, whereas it did not alter the Akt protein level. The induction of Akt phosphorylation was maximum
by the treatment of vanadate at 100 M. To study the kinetics
on Akt phosphorylation induced by vanadate, cells were
treated with 100 M vanadate for 0 – 4 h, and total cellular
protein extracts were used for the assay of phospho-Akt
(Ser473) and Akt protein levels. As shown in Fig. 3D, vanadate
induced Akt phosphorylation in a time-dependent manner,

whereas it did not affect Akt protein level. The maximum
induction of Akt phosphorylation occurred 2 h after the addition of vanadate. These results suggest that vanadate-induced
PI3K activity and Akt phosphorylation, and further confirmed
that PI3K/Akt pathway was required for vanadate-induced
HIF-1␣ expression.
Effect of PI3K Inhibitors on Vanadate-induced PI3K Activity
and Akt Phosphorylation—To further investigate whether vanadate-induced HIF-1␣ expression through the PI3K/Akt pathway, DU145 cells were cultured in MEM supplemented with
10% FBS for 24 h, followed by the addition of LY294002 and
wortmannin, respectively, 30 min prior to treatment with 100
M vanadate for 2 h. Cellular protein extracts were used for
analysis of PI3K activity and Akt phosphorylation. As shown in
Fig. 4A, both LY294002 and wortmannin inhibited PI3K activity induced by vanadate. Similarly, these PI3K inhibitors also
inhibited the phosphorylation of Akt at Ser473 induced by
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FIG. 10. Effects of antioxidants on vanadate-induced HIF-1
expression, Akt phosphorylation, and VEGF protein secretion.
DU145 cells were cultured in MEM supplemented with 10% FBS for
24 h at 37 °C in a 5% CO2 incubator, followed by pretreatment with
various antioxidants for 30 min. Cells were then incubated with 100 M
vanadate for 6 (A) and 2 (B) h. Whole cell extracts were prepared and
subjected to immunoblot assay with antibodies against HIF-1␣ and
HIF-1␤ (A), and phospho-Akt (Ser473) and Akt (B). C, the cells were
seeded in a 6-well plate at a density of 1 ⫻ 106 cells/well in MEM
supplemented with 10% FBS and incubated for 24 h at 37 °C in 5%
CO2, followed by incubation with antioxidants for 30 min prior to the
treatment with 50 M vanadate for 24 h, VEGF protein concentrations in the cell culture media were determined by ELISA (C). The
results represent the mean values of VEGF concentration from three
separate experiments and duplicate samples of each experiment.
Mean ⫾ S.E. values are plotted: **, p ⬍ 0.01 compared with the
control; # and ##, p ⬍ 0.05 and p ⬍ 0.01, respectively, compared with
the values from the cells treated by vanadate in the absence of the
antioxidants. ***, p ⬍ 0.01 compared with the vanadate-treated
group. SOD, superoxide dismutase.

vanadate (Fig. 4, B and C), suggesting that vanadate-induced
Akt phosphorylation was through PI3K activation, and further
confirming that the PI3K/Akt pathway was required for induction of HIF-1␣ expression induced by vanadate.
Role of mTOR/FRAP in HIF-1 Expression—To investigate
whether rapamycin, a mTOR/FRAP inhibitor, could inhibit
HIF-1␣ expression induced by vanadate, DU145 cells were
cultured in MEM supplemented with 10% FBS for 24 h, followed by the addition of rapamycin 30 min prior to the treatment of 100 M vanadate for 6 h. Cellular lysates were prepared and used to determine HIF-1␣ and HIF-1␤ protein levels.
As shown in Fig. 5, rapamycin inhibited vanadate-induced

31969

HIF-1␣ expression in a dose-dependent manner, whereas rapamycin did not cause any decrease in HIF-1␤ protein level.
The results suggest that mTOR/FRAP, a downstream target of
PI3K/Akt, was required for HIF-1␣ expression induced by
vanadate.
Induction of VEGF Expression—HIF-1 is known to activate
VEGF expression in response to low oxygen. To investigate
whether induction of HIF-1␣ expression by vanadate results in
an increase in HIF-1-regulated gene expression, the level of
VEGF protein in DU145 cells after exposure of vanadate was
analyzed using ELISA. Treatment of cells with 50 M vanadate
significantly increased VEGF levels in a time-dependent manner, when compared with VEGF levels in untreated cells
(Fig. 6).
Effect of PI3K Inhibitors and MAP Kinase Kinase Inhibitor
on VEGF Expression—To investigate whether PI3K and MEK
were involved in the expression of VEGF, DU145 cells were
cultured in MEM supplemented with 10% FBS for 24 h, followed by the addition of PI3K inhibitors, LY294002 and wortmannin, or the MEK inhibitor, PD98059, 30 min prior to the
treatment of vanadate. Cells were then treated with 50 M
vanadate for 24 h. VEGF protein concentration in the media
was determined by ELISA. As shown in Fig. 7, LY294002 and
wortmannin significantly decreased the VEGF protein levels
induced by vanadate, whereas MEK inhibitor, PD98059, did
not exhibit any inhibitory effect. These results further suggest
that PI3K signaling was required for induction of HIF-1␣ and
VEGF expression induced by vanadate, whereas MEK activity
was not required.
Requirement of ROS for Induction of HIF-1␣ Expression—
ROS are known to play a major role in vanadate-induced carcinogenesis (44, 45). To determine whether vanadate could
induce HIF-1␣ expression through ROS, we first examined the
ROS generation in the vanadate-treated cells. The ability of
vanadate to generate 䡠OH radicals was examined using an ESR
spin trapping method with DMPO as the spin trap. DU145 cells
alone exhibited a weak ESR signal from the impurity in the
spin trap, but did not produce any detectable amount of free
radicals (Fig. 8A). The cells incubated with vanadate generated
a typical ESR spectrum because of cellular reduction of vanadate in phosphate-buffered solution (pH 7.4) (Fig. 8B). The
spectrum consists of a 1:2:2:1 quartet with a splitting of aH ⫽
aN ⫽ 14.9 G, where aN and aH denote the hyperfine splitting of
the nitroxyl nitrogen and ␣-hydrogen, respectively. Based on
these splittings and the 1:2:2:1 line shape, this spectrum was
assigned to the DMPO/䡠OH adduct, which was evidence of 䡠OH
radical generation. Addition of superoxide dismutase, a O2.
scavenger whose function was to convert O2. to H2O2, markedly
increased the DMPO/䡠OH adduct signal (Fig. 8C). Catalase, an
H2O2 scavenger, decreased the generation of 䡠OH radical (Fig.
8D); sodium formate, a scavenger of 䡠OH radical, also decreased
the intensity of the DMPO/䡠OH signal (Fig. 8E). NADPH, a
cofactor of certain flavoenzymes such as glutathione reductase,
which catalyzes the reduction of vanadate to vanadium(IV),
markedly enhanced the generation of the 䡠OH radical (Fig. 8F).
To determine whether NADPH oxidase or the mitochondria
electron transport chain could play an important role in vanadate-induced ROS generation, DPI, a NADPH oxidase inhibitor, and rotenone, a mitochondria electron transport interrupter, were used. As shown in Fig. 8, G and H, both DPI and
rotenone reduced 䡠OH radical generation induced by vanadate.
The data were similar in three independent experiments (Table
I). These results indicated that both NADPH oxidase and mitochondria electron transport chain contributed to vanadate(V)-induced ROS generation.
The ability of vanadate to generate H2O2 in DU145 cells was
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analyzed by a quantitative H2O2 assay kit. In the presence of
vanadate, H2O2 was dramatically enhanced compared with
control, whereas catalase, an H2O2 scavenger, markedly suppressed the formation of H2O2 (Fig. 9A).
A specific fluorescent dye was used to visualize free radical
generation directly inside the DU145 cells. HE, a specific fluorescent dye for O2. , was used to detect the generation of O2. .
The cells were visualized with a laser scanning confocal microscope (Fig. 9B). Because this oxygen species was mainly produced in the mitochondria, the bright color fluorescent dots in
the cytoplasm represent the subcellular location of the O2. (Fig.
9B). Compared with control, vanadate treatment enhanced
O2. radical production, whereas addition of superoxide dismutase suppressed its production to basal level (Fig. 9B). HE
exhibits a red or orange color after being oxidized by O2. . Because O2. was the one-electron reduction product of molecular
oxygen, the O2 consumption in cells treated with vanadate was
measured using a Gilson oxygraph equipped with a Clark electrode. As shown in Fig. 9C, vanadate increased O2 consumption, and addition of NADPH further enhanced it.
Involvement of ROS in HIF-1␣ and VEGF Expression and
Akt Phosphorylation—To understand whether ROS generated
by vanadate in DU145 play a role in vanadate-induced HIF-1␣
expression through the PI3K pathway, the effects of various
antioxidants on vanadate-induced HIF-1␣ expression and Akt
phosphorylation were determined using immunoblot assay. As
shown in Fig. 10, A and B, treatment of the cells with 100 M
vanadate-induced HIF-1␣ expression and Akt phosphorylation.
Catalase, an H2O2 scavenger, inhibited both vanadate-induced
HIF-1␣ expression and Akt phosphorylation. Sodium formate,
a 䡠OH radical scavenger, slightly inhibited HIF-1␣ expression
and Akt phosphorylation. In contrast, treatment of cells with
superoxide dismutase did not inhibit HIF-1␣ expression or Akt
phosphorylation. To further study the role of ROS in HIF-1regulated gene expression, the effects of various specific antioxidants on vanadate-induced VEGF expression were determined using ELISA. As shown in Fig. 10C, treatment of cells
with vanadate increased VEGF protein levels, and addition of
catalase significantly inhibited VEGF expression. Sodium formate did not significantly affect the VEGF level, which may be
because of the decrease of HIF-1 expression (Fig. 10A). In
contrast, treatment of cells with superoxide dismutase did not
significantly inhibit the VEGF expression induced by
vanadate.
DISCUSSION

The results obtained from this study show that vanadate was
able to induce HIF-1␣ and VEGF protein expression in a doseand time-dependent manner in DU145 cells, whereas HIF-1␤
protein expression was not affected by vanadate treatment. It
has been reported that HIF-1␤ is not significantly affected by
cellular oxygen tension (3). HIF-1␣ protein is rapidly degraded
under normoxic condition by the ubiquitin-proteasome system
(54, 55), whereas hypoxia and CoCl2 (56, 57) induce both the
stabilization and the transactivation of HIF-1␣ (34, 35). It has
also been reported that insulin, like hypoxia, induces HIF-1␣
expression (46 – 49). Because vanadium has been found to act in
an insulin-like manner, vanadate may increase HIF-1␣ expression by a similar signal pathway as insulin and hypoxia. It is
known that HIF-1 activates VEGF expression by directly binding to VEGF promoter in response to hypoxia (2, 3, 58). Similarly, the induction of HIF-1 by vanadate resulted in an increased level of VEGF expression. There is a strong correlation
between VEGF expression and cancer progression and metastasis (22). Inhibition of VEGF expression has a dramatic effect
on tumor growth, invasion, and metastasis (24, 25, 59 – 66). It is

FIG. 11. Schematic representation of possible mechanism of
vanadate-induced HIF-1 and VEGF expression.

possible that the induction of HIF-1 and VEGF may play an
important role in vanadate-induced carcinogenesis.
The present study also indicates that the PI3K/AKT/FRAP
signaling pathway was required for induction of HIF-1 and
VEGF expression induced by vanadate, whereas the mitogenactivated protein kinase/ERK pathway was not involved. The
following results provide the evidence to support this conclusion: (a) PI3K inhibitors, LY294002 and wortmannin, inhibited
HIF-1␣ expression induced by vanadate, whereas MEK inhibitor, PD98059, did not; (b) vanadate-induced PI3K activity in a
dose- and time-dependent manner, and LY294002 and wortmannin inhibited the vanadate-induced PI3K activity; (c) vanadate induced Akt phosphorylation in a dose- and time-dependent manner, and LY294002 and wortmannin inhibited the Akt
phosphorylation; (d) rapamycin, a mTOR/FRAP inhibitor, inhibited HIF-1␣ expression induced by vanadate in a dose-dependent manner; and (e) LY294002 and wortmannin decreased
the VEGF protein level induced by vanadate in a dose-dependent manner, whereas the MEK inhibitor, PD98059, did not
exhibit any effect. These data suggest that activation of the
PI3K/AKT/mTOR signaling pathway and induction of HIF-1
and VEGF expression could be an important mechanism to
understand the vanadate-induced carcinogenesis.
Our study also indicates that ROS are involved in vanadateinduced HIF-1␣ and VEGF expression. Among them, H2O2
plays a critical role based on the following evidence: (a) exposure of cells to vanadate-generated H2O2 as determined by
quantitative H2O2 assay; (b) ESR spin trapping measurements
show that cells pretreated with vanadate generated 䡠OH radical using H2O2 as a precursor; (c) vanadate increased the rate
of cellular oxygen consumption; (d) catalase, a specific scavenger of H2O2, decreased the generation of ROS induced by
vanadate; (e) catalase inhibited HIF-1␣ and VEGF expression
and Akt phosphorylation induced by vanadate, whereas sodium formate, a scavenger of 䡠OH, showed a minor effect; and
(f) superoxide dismutase, a scavenger of O2. , did not inhibit
vanadate-induced HIF-1␣ and VEGF expression or AKT phosphorylation. It may be noted that catalase, a scavenger of
H2O2, abolished the hypoxia- and CoCl2-induced stabilization
of HIF-1␣, and exogenous H2O2 stabilized HIF-1␣ expression
during normoxia, suggesting that H2O2 acts as a signaling
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element in this response (64). The mechanism of ROS generation induced by vanadate could be that in the presence of
NADPH and several cellular flavoenzymes (such as glutathione
reductase, lipoyl dehydrogenase, ferredoxin-NADP⫹, and
NADPH oxidase) the mitochondria electron transport chain is
able to reduce vanadate to vanadium(IV) (44). During the reduction process, molecular oxygen was consumed to generate
O2. , which was subsequently converted to H2O2 through superoxide dismutase dismutation (Fig. 11). Vanadium(IV) is also
able to generate 䡠OH radical from H2O2 via a Fenton-like reaction (44, 52, 64).
Molecular oxygen is the original source of ROS generation in
DU145 cells under vanadate stimulation as demonstrated by
the oxygen consumption assay. The major pathways involved
in ROS generation are both the flavoprotein-containing
NADPH oxidase complex and the mitochondrial electron transport chain. This conclusion is supported by the inhibition of
ROS generation by DPI, a flavoprotein inhibitor, as well as
rotenone, an inhibitor of the mitochondrial electron chain as
determined by ESR measurements. In conclusion, this work
demonstrates that vanadate is able to induce HIF-1␣ and
VEGF expression via the PI3K/AKT/mTOR/FRAP signaling
pathway. H2O2 generated during the cellular reduction of vanadate is the major species responsible for vanadate-induced
expression of HIF-1␣ and VEGF. Further study of the role of
HIF-1␣ and VEGF expression in vanadate-induced carcinogenesis will be the next important challenge.
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